SURROGATE ENDPOINTS FOR OVERALL SURVIVAL (OS) IN ADVANCED MELANOMA: A TARGETED LITERATURE REVIEW (TLR) OF CORRELATION META-ANALYSES

被引：0
|
作者：
Pourrahmat, M. M. [1 ]
Leung, L. [1 ]
Kurt, M. [2 ]
Chou, E. [2 ]
Kanters, S. [1 ]
Moshyk, A. [2 ]
Hamilton, M. [2 ]
机构：
[1] Evidinno Outcomes Res Inc, Vancouver, BC, Canada
[2] Bristol Myers Squibb, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC24
引用
收藏
页码：S37 / S37
页数：1
相关论文
共 50 条
  • [21] Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
    Litao Huang
    Deying Kang
    Chongyang Zhao
    Xueting Liu
    Scientific Reports, 14
  • [22] Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
    Huang, Litao
    Kang, Deying
    Zhao, Chongyang
    Liu, Xueting
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [23] Overall survival (OS) in the management of pretreated patients with unresectable stage III/IV melanoma: A systematic literature review and meta-analysis.
    Kotapati, S.
    Dequen, P.
    Ouwens, M.
    van Baardewijk, M.
    Ibrahim, R. A.
    Wagner, S.
    Jansen, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: A systematic literature review
    Branchoux, Sebastien
    Bellera, Carine
    Italiano, Antoine
    Rustand, Denis
    Gaudin, Anne-Francoise
    Rondeau, Virginie
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 137 : 35 - 42
  • [25] Investigating surrogate endpoints (SE) for overall survival (OS) in first-line (1L) advanced melanoma: A pooled-analysis of immune checkpoint inhibitor (ICI) trials
    Larkin, J.
    Squifflet, P.
    Saad, E. D.
    Mohr, P.
    Kurt, M.
    Moshyk, A.
    Hamilton, M.
    Kotapati, S.
    Buyse, M. E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S919 - S920
  • [26] TARGETED LITERATURE REVIEW (TLR) OF THE ECONOMIC BURDEN AND COST-EFFECTIVENESS OF TREATMENTS FOR ADVANCED/METASTATIC MELANOMA
    McGovern, A.
    Jiang, R.
    Fountain, D.
    Brown, R.
    Ioannou, P.
    White, M.
    VALUE IN HEALTH, 2021, 24 : S30 - S30
  • [27] Surrogate endpoints for overall survival (OS) in advanced pancreatic cancer (APC): Analysis of randomized clinical trials (RCTs) exploring gemcitabine (G)-based combinations
    Milella, M.
    Bria, E.
    Carlini, P.
    Cuppone, F.
    Gelibter, A.
    Nistico, C.
    Ruggeri, E. M.
    Terzoli, E.
    Cognetti, F.
    Giannarelli, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis
    Sala, Isabella
    Pagan, Eleonora
    Pala, Laura
    Oriecuia, Chiara
    Musca, Marco
    Specchia, Claudia
    De Pas, Tommaso
    Cortes, Javier
    Giaccone, Giuseppe
    Postow, Michael
    Gelber, Richard D.
    Bagnardi, Vincenzo
    Conforti, Fabio
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [29] Potential Surrogate Endpoints for Progression-Free Survival (PFS) and Overall Survival (OS) in Non-Hodgkin Lymphoma: A Literature-Based Meta-analysis of Phase II and Phase III Studies
    Zhu, Rui
    Lu, Dan
    Chu, Wayne
    Chai, Akiko
    Green, Michelle
    Zhang, Nancy
    Jin, Jin Yan
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S78 - S78
  • [30] RECURRENCE-FREE SURVIVAL (RFS) AS A SURROGATE ENDPOINT (SE) FOR OVERALL SURVIVAL (OS) IN RESECTED STAGE II/III MELANOMA: A CORRELATION META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (RCTS)
    Leung, L.
    Kirkwood, J.
    Srinivasan, S.
    Dyer, M.
    Qian, A.
    Pourrahmat, M. M.
    Kasireddy, E.
    May, J. R.
    Moshyk, A.
    Kurt, M.
    VALUE IN HEALTH, 2023, 26 (12) : S24 - S24
12345